The aim of this review was to compare third generation aromatase inhibitors (AIs) to antioestrogens and progestins in the treatment of post-menopausal women with hormone receptor-positive metastatic breast cancer.
|File size:||1.32 MB|
|Cancer Type:||Breast cancer|
|Publication Audience:||Resources for health professionals|
|Document Status:||Research and data reports
This resource is 5 years or older. It includes data or research findings at an earlier point in time and is available to the public for research and reference purposes.